同源康医药-B(02410)发布公告,公司已于2025年6月6日向中国证券监督管理委员会提交申请,计划将461万股非上市股份转换为H股并在香港联合交易所上市。此次申请是依据相关法律法规及监管指引进行的,标志着公司向H股全流通迈出了重要一步。根据公告,转化的非上市股份占公司已发行股本总额3.71亿股的1.24%。在获得所有相关监管机构的批准后,这些股份将能够在联交所主板上市交易。公司将持续关注申请...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.